CA2182583A1 - Enantiomerically pure (+)-liarozole - Google Patents

Enantiomerically pure (+)-liarozole

Info

Publication number
CA2182583A1
CA2182583A1 CA002182583A CA2182583A CA2182583A1 CA 2182583 A1 CA2182583 A1 CA 2182583A1 CA 002182583 A CA002182583 A CA 002182583A CA 2182583 A CA2182583 A CA 2182583A CA 2182583 A1 CA2182583 A1 CA 2182583A1
Authority
CA
Canada
Prior art keywords
compound
acid
formula
mixture
liarozole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002182583A
Other languages
English (en)
French (fr)
Inventor
Marc Gaston Venet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2182583A1 publication Critical patent/CA2182583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002182583A 1994-02-18 1995-02-10 Enantiomerically pure (+)-liarozole Abandoned CA2182583A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94200420.1 1994-02-18
EP94200420 1994-02-18
PCT/EP1995/000490 WO1995022540A1 (en) 1994-02-18 1995-02-10 Enantiomerically pure (+)-liarozole

Publications (1)

Publication Number Publication Date
CA2182583A1 true CA2182583A1 (en) 1995-08-24

Family

ID=8216652

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002182583A Abandoned CA2182583A1 (en) 1994-02-18 1995-02-10 Enantiomerically pure (+)-liarozole

Country Status (12)

Country Link
EP (1) EP0745077A1 (xx)
JP (1) JPH09508914A (xx)
CN (1) CN1141042A (xx)
AU (1) AU689206B2 (xx)
CA (1) CA2182583A1 (xx)
IL (1) IL112688A0 (xx)
MX (1) MX9603316A (xx)
NZ (1) NZ279227A (xx)
SG (1) SG52325A1 (xx)
TW (1) TW401415B (xx)
WO (1) WO1995022540A1 (xx)
ZA (1) ZA951343B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019991A1 (en) * 1994-12-28 1996-07-04 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
EP1992228A1 (en) * 2007-05-14 2008-11-19 Bayer CropScience AG Insecticidal substituted thiourea derivatives
US9138393B2 (en) * 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) * 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders

Also Published As

Publication number Publication date
TW401415B (en) 2000-08-11
EP0745077A1 (en) 1996-12-04
NZ279227A (en) 1997-11-24
CN1141042A (zh) 1997-01-22
WO1995022540A1 (en) 1995-08-24
JPH09508914A (ja) 1997-09-09
MX9603316A (es) 1997-02-28
ZA951343B (en) 1996-08-19
AU1578795A (en) 1995-09-04
IL112688A0 (en) 1995-05-26
AU689206B2 (en) 1998-03-26
SG52325A1 (en) 1998-09-28

Similar Documents

Publication Publication Date Title
KR100365312B1 (ko) N-[4-(헤테로아릴메틸)페닐]헤테로아릴아민
CA2151730C (en) New crystalline form of a vitamin d analogue
JP2912596B2 (ja) ベンズイミダゾール誘導体
DE2950019A1 (de) Imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
CH622254A5 (xx)
MX2013003008A (es) Profarmacos de ester de [-3(1-(1h-imidazol-4-il)etil)-2-metilfenil ]metanol para el tratamiento de enfermedades y afecciones de la piel.
RU2152933C2 (ru) Ацилированные аминоалкилимидазолы, способ их получения и фармацевтическая композиция
CA2182583A1 (en) Enantiomerically pure (+)-liarozole
RU2165419C2 (ru) 6-[триазолил-[3-(трифторметил)фенил]метил]-2-хинолиноны и -хинолинтионы, композиция и способ ее получения
JPS63107979A (ja) 新規化合物、その製法及びそれを含む医薬組成物
HUT62884A (en) Process for producing 4-|4-/4-(4-hydroxyphenyl)-1-piperazinyl/-phenyl¨-5-methyl-3h-1,2,4-triazol-3-one derivatives and pharmaceutical compositions comprising same
JPH02243673A (ja) シクロプロピル置換アゾリルメチルカルビノール誘導体、その製造方法及び医薬としてのその用途
US5312815A (en) Fungicidal (+)-2-(2,4-difluorophenyl)-3-methyl-1-(1H-1,2,4-triazol-1-yl)3-(6-(1H-1,2,4-triazol-1-yl)pyridazin-3-ylthio) butan-2-ol
EP0194580B1 (de) Neue Imidazolylverbindungen und Verfahren zu ihrer Herstellung
WO1995022541A1 (en) Enantiomerically pure(-)-liarozole
EP0800391A1 (en) Benzimidazoles as inhibitors of calcitriol metabolism
CA2074833A1 (fr) Derives d'(alkylthio-3 propyl)-3 benzothiazoline, leur preparation et les medicaments les contenant
CA2182581A1 (en) Enantiomerically pure(-)-liarozole
PL97706B1 (pl) Sposob wytwarzania nowych pirazolidynonow
MXPA97004667A (en) 6- [triazolil [3-trifluoromethyl) phenyl] methyl] -2-quinolinones and quinolinotium
KR880007482A (ko) 치료학적 활성도를 가지는 신규의 이미다졸 유도체, 이의 제조방법 및 이들을 포함하는 제약학적 조성물.
DE3732388A1 (de) Azolylmethylcyclopropyl-carbinole enthaltende antimykotische mittel
PL182101B1 (pl) Nowe pochodne acylowanych aminoalkanoimidazoli i srodek farmaceutyczny do selektywnego inhibitowania hydroksylaz 25-hydroksywitaminy D3 PL
NZ236785A (en) Naphthalen-1-ol esters, and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FZDE Discontinued